DEF 14A: Oscar Health Files Proxy Statement for 2024 Annual Stockholders Meeting

Oscar Health has filed its proxy statement for the 2024 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, and executive compensation approval.

Summary

• Oscar Health has released its proxy statement for the 2024 Annual Meeting of Stockholders, scheduled for June 6, 2024.
• The meeting will be held virtually.
• Stockholders of record as of April 10, 2024, are entitled to vote.
• The proposals include the election of ten directors, ratification of PricewaterhouseCoopers LLP as the independent accounting firm for fiscal year 2024, and an advisory vote on executive compensation.
• The Board of Directors recommends voting FOR all listed proposals.
• The proxy statement details corporate governance practices, director independence, and executive compensation.
• The document also outlines related person transactions and provides information on stock ownership by beneficial owners and management.
• The company achieved several key milestones in 2023, including InsuranceCo Adjusted EBITDA profitability and improvements in Medical Loss Ratio and Administrative Expense Ratio.
• Executive compensation includes base salary, annual performance-based incentives, and equity-based long-term incentives.
• The Talent and Compensation Committee approved performance goals for the annual bonus program that were intended to reward successful execution of the business plan and achievement of short-term strategic priorities.
• The Talent and Compensation Committee determined to pay out annual bonuses at 135% of target for each of our NEOs (other than Mr. Sankaran, who was not eligible for cash incentives).
• The company's CEO pay ratio for 2023 was 455 to 1, with the median employee compensation at $98,350 and the CEO's total compensation at $44,748,864.
• The company has adopted a compensation recovery policy as required by Rule 10D-1 under the Exchange Act and the corresponding NYSE listing standards.

Sentiment

Score: 7

Explanation: The document presents a balanced view, highlighting both positive financial achievements and ongoing challenges. The tone is professional and forward-looking, suggesting cautious optimism.

Positives

• The company achieved InsuranceCo Adjusted EBITDA profitability.
• The company improved its Medical Loss Ratio by 370 basis points year-over-year.
• The company improved its InsuranceCo Administrative Expense Ratio by 270 basis points year-over-year.
• The company improved its InsuranceCo Combined Ratio of by 640 basis points year-over-year.
• The company improved its Adjusted Administrative Expense Ratio by 350 basis points year-over-year.
• The company improved its Net loss of $271 million, an improvement of $339 million year-over-year.
• The company improved its Adjusted EBITDA loss of $45 million, an improvement of $417 million year-over-year.
• The company has a clawback policy in place for incentive compensation.
• The company has stock ownership guidelines for executives and directors.

Negatives

• Direct and assumed premiums decreased by 3% year-over-year to $6.6 billion.
• The company reported a net loss of $271 million.
• The company reported an Adjusted EBITDA loss of $45 million.

Risks

• The company's ability to execute its strategy and manage growth effectively is a risk.
• The company faces heightened competition in its markets.
• The company's ability to accurately estimate medical expenses and manage medical costs is a risk.
• Changes in federal or state laws and regulations, including the ACA, could impact the company.
• The company faces risks related to compliance with regulatory requirements and data security breaches.
• Adverse publicity or other adverse consequences related to our dual class structure or controlled company status is a risk.

Future Outlook

The company expects to achieve consolidated Adjusted EBITDA profitability in 2024.

Management Comments

• Mark T. Bertolini, Chief Executive Officer, expressed gratitude for stockholder support and urged prompt proxy voting.
• Management delivered strong 2023 results with most core metrics exceeding expectations for the full year.
• Management also delivered on its commitment for InsuranceCo Adjusted EBITDA profitability, and ended the year with a clear line of sight into consolidated Adjusted EBITDA profitability in 2024.

Industry Context

The proxy statement reflects standard corporate governance practices for publicly traded companies in the health insurance and technology sectors, including executive compensation structures, board composition, and risk oversight.

Comparison to Industry Standards

• The executive compensation structure, including base salary, bonus, and equity awards, aligns with industry standards for healthcare and technology companies of similar size and complexity.
• The company's corporate governance practices, such as director independence and committee oversight, are consistent with NYSE listing requirements and best practices.
• The use of a peer group for benchmarking executive compensation is a common practice among publicly traded companies.
• The company's clawback policy and stock ownership guidelines are in line with regulatory requirements and promote alignment with shareholder interests.
• The company's CEO pay ratio of 455 to 1 is higher than some industry peers, but is not uncommon for companies with significant equity-based compensation.

Management Changes

Corporate Governance

Related Party Transactions

• The company entered into a services agreement with an affiliate of Sanford Health, where board member William Gassen III is the CEO, for campaign builder and related services.
• Entities affiliated with Thrive Capital, where board member Joshua Kushner is the Founder and CEO, purchased $35 million of the company's 7.25% Convertible Senior Notes due 2031.
• The company is party to an Investors Rights Agreement with certain holders of its capital stock, including entities affiliated with Alphabet Holdings LLC, Formation8, Founders Fund, Fidelity, General Catalyst Group, Khosla Ventures, and Thrive Capital, some of which are beneficial holders of more than 5% of our capital stock or are entities with which certain of our directors are affiliated.
• The company has entered into various technology service agreements with affiliates of Alphabet Holdings LLC, who was a beneficial holder of more than 5% of our capital stock during 2023, pursuant to which such affiliates have agreed to provide us with technology infrastructure and enterprise services.

Stakeholder Impact

• Shareholders are asked to vote on key proposals that will shape the company's direction and governance.
• Employees are impacted by the company's compensation policies and benefits programs.
• Members benefit from the company's efforts to improve access to care and personalize the healthcare experience.
• The company's relationships with providers and vendors are essential for delivering quality care.
• The company's financial performance and regulatory compliance impact its ability to meet its obligations to creditors.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting of Stockholders on June 6, 2024.
• The Board and Talent and Compensation Committee will consider the outcome of the advisory vote on executive compensation in future compensation decisions.

Key Dates

Keywords

proxy statement, annual meeting, stockholders, corporate governance, executive compensation, director election, PricewaterhouseCoopers, audit committee, Oscar Health, healthcare